Increased Serum Enzyme Levels Associated with Kupffer Cell Reduction with No Signs of Hepatic or Skeletal Muscle Injury

Department of Biotherapeutics Research & Development, Pfizer Worldwide Research and Development, Cambridge, MA 02140, USA.
American Journal Of Pathology (Impact Factor: 4.59). 07/2011; 179(1):240-7. DOI: 10.1016/j.ajpath.2011.03.029
Source: PubMed


Macrophage colony-stimulating factor (M-CSF) is a hematopoietic growth factor that is responsible for the survival and proliferation of monocytes and the differentiation of monocytes into macrophages, including Kupffer cells (KCs) in the liver. KCs play an important role in the clearance of several serum enzymes, including aspartate aminotransferase and creatine kinase, that are typically elevated as a result of liver or skeletal muscle injury. We used three distinct animal models to investigate the hypothesis that increases in the levels of serum enzymes can be the result of decreases in KCs in the apparent absence of hepatic or skeletal muscle injury. Specifically, neutralizing M-CSF activity via a novel human monoclonal antibody reduced the CD14(+)CD16(+) monocyte population, depleted KCs, and increased aspartate aminotransferase and creatine kinase serum enzyme levels in cynomolgus macaques. In addition, the treatment of rats with clodronate liposomes depleted KCs and led to increased serum enzyme levels, again without evidence of tissue injury. Finally, in the osteopetrotic (Csf1(op)/Csf1(op)) mice lacking functional M-CSF and having reduced levels of KCs, the levels of serum enzymes are higher than in wild-type littermates. Together, these findings support a mechanism for increases in serum enzyme levels through M-CSF regulation of tissue macrophage homeostasis without concomitant histopathological changes in either the hepatic or skeletal system.

Full-text preview

Available from:
  • Source
    • "CPZ in combination with LPS or LTA increased the levels of serum transaminases and depleted glycogen without causing hepatocellular damage. Increase in the levels of serum transaminase such as AST and ALT have been shown previously without the detection of liver injury by immunohistochemistry analysis (Radi et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation is a major component of idiosyncratic adverse drug reactions (IADRs). To understand the molecular mechanism of inflammation-mediated IADRs, we determined the role of the Toll-like receptor (TLR) signaling pathway in idiosyncratic hepatotoxicity of the anti-psychotic drug, chlorpromazine (CPZ). Activation of TLRs recruits the first adaptor protein, Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) to the TIR domain of TLRs leading to the activation of the downstream kinase, c-Jun-N-terminal kinase (JNK). Prolonged activation of JNK leads to cell-death. We hypothesized that activation of TLR2 by lipoteichoic acid (LTA) or TLR4 by lipopolysaccharide (LPS) will augment the hepatotoxicity of CPZ by TIRAP-dependent mechanism involving prolonged activation of JNK. Adult male C57BL/6, TIRAP(+/+) and TIRAP(-/-) mice were pretreated with saline, LPS (2mg/kg) or LTA (6mg/kg) for 30min or 16h followed by CPZ (5mg/kg) or saline (vehicle) up to 24h. We found that treatment of mice with CPZ in presence of LPS or LTA leads to ~3-4 fold increase in serum ALT levels, a marked reduction in hepatic glycogen content, significant induction of serum tumor necrosis factor (TNF) α and prolonged JNK activation, compared to LPS or LTA alone. Similar results were observed in TIRAP(+/+) mice, whereas the effects of LPS or LTA on CPZ-induced hepatotoxicity were attenuated in TIRAP(-/-) mice. For the first time, we show that inflammation-mediated hepatotoxicity of CPZ is dependent on TIRAP, and involves prolonged JNK activation in vivo. Thus, TIRAP-dependent pathways may be targeted to predict and prevent inflammation-mediated IADRs.
    Full-text · Article · Dec 2012 · Toxicology and Applied Pharmacology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The most widely available laboratory tests of liver integrity, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and bilirubin, are not always helpful in the diagnosis and management of drug-induced liver injury (DILI). These tests do not distinguish DILI from other types of liver injuries, or identify which specific drug is responsible when DILI occurs in a patient receiving multiple medications. In addition, current liver tests cannot reliably distinguish at an early stage DILI that may represent a serious health risk from DILI that will reverse with continued drug therapy. Finally, given the practical and ethical issues involved in obtaining liver biopsies in patients experiencing DILI, it would be ideal to have biomarkers in accessible body fluids that could serve as surrogates to liver biopsies to better define mechanisms underlying DILI. Realizing these pressing clinical and research needs, there are now major research efforts under way to identify novel biomarkers of DILI. Validating these DILI biomarkers will require the establishment of well-annotated serum and urine banks from patients experiencing DILI.
    No preview · Article · Jul 2010 · Therapy
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrophage-colony stimulating factor (CSF-1) signaling through its receptor (CSF-1R) promotes the differentiation of myeloid progenitors into heterogeneous populations of monocytes, macrophages, dendritic cells, and bone-resorbing osteoclasts. In the periphery, CSF-1 regulates the migration, proliferation, function, and survival of macrophages, which function at multiple levels within the innate and adaptive immune systems. Macrophage populations elicited by CSF-1 are associated with, and exacerbate, a broad spectrum of pathologies, including cancer, inflammation, and bone disease. Conversely, macrophages can also contribute to immunosuppression, disease resolution, and tissue repair. Recombinant CSF-1, antibodies against the ligand and the receptor, and specific inhibitors of CSF-1R kinase activity have been each been tested in a range of animal models and in some cases, in patients. This review examines the potential clinical uses of modulators of the CSF-1/CSF-1R system. We conclude that CSF-1 promotes a resident-type macrophage phenotype. As a treatment, CSF-1 has therapeutic potential in tissue repair. Conversely, inhibition of CSF-1R is unlikely to be effective in inflammatory disease but may have utility in cancer.
    Preview · Article · Dec 2011 · Blood
Show more